You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博瑞醫藥(688166.SH):BGM0504注射液減重適應症獲得Ⅲ期臨牀試驗倫理批件
格隆匯 10-21 16:24

格隆匯10月21日丨博瑞醫藥(688166.SH)公佈,全資子公司博瑞新創生物醫藥科技(無錫)有限公司自主研發的BGM0504注射液減重適應症的Ⅲ期臨牀研究方案通過了牽頭醫院北京大學人民醫院倫理審查委員會的審批,獲得了《北京大學人民醫院倫理審查委員會倫理審查批件》。

BGM0504注射液是公司自主研發的GLP-1(胰高血糖素樣肽1)和GIP(葡萄糖依賴性促胰島素多肽)受體雙重激動劑,屬於境內外均未上市化學藥品1類創新藥。BGM0504注射液可激動GIP和GLP-1下游通路,產生控制血糖、減重和治療非酒精性脂肪性肝炎(NASH)等生物學效應,展現多種代謝疾病治療潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account